Results 51 to 60 of about 302,208 (172)

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors

open access: yesViruses, 2015
Oncolytic viruses represent a diverse class of replication competent viruses that curtail tumor growth. These viruses, through their natural ability or through genetic modifications, can selectively replicate within tumor cells and induce cell death ...
Karishma R. Rajani, Richard G. Vile
doaj   +1 more source

Cryo‐EM Analysis of Adenovirus Vector Reveals Purification Conditions Leading to Loss of Viral Fiber Proteins and Reduced Infectivity

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Vaccines and gene therapies require efficient delivery of genetic material to host cells. Viral vectors leverage viruses' ability to enter host cells to achieve this. Following the SARS‐CoV‐2 vaccine and novel gene therapies that utilize adenovirus vectors, there has been an increase in the demand for large‐scale production of vectors.
Betsy Widdicombe   +7 more
wiley   +1 more source

Effects of Concomitant Medications on Clinical and Immunological Outcomes of Cancer Patients Treated With Oncolytic Adenoviruses

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Medication taken for other reasons than for the treatment of malignant disease, termed concomitant medication, is known to affect outcomes when used with immune checkpoint inhibitor therapy and other oncological drugs. However, no research in humans has addressed the relationship between concomitant medications and efficacy of oncolytic ...
Santeri A. Pakola   +20 more
wiley   +1 more source

Current strategies in engaging oncolytic viruses with antitumor immunity

open access: yesMolecular Therapy: Oncolytics, 2021
Oncolytic virotherapy has produced promising yet limited results in preclinical and clinical studies. Besides direct oncolytic activity, a significant therapeutic mechanism of oncolytic virotherapy is the induction of tumor-specific immunity ...
Drew Ashton Boagni   +2 more
doaj   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

open access: yesiNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid   +4 more
wiley   +1 more source

Fusogenic Viruses in Oncolytic Immunotherapy

open access: yes, 2018
Oncolytic viruses are under intense development and have earned their place among the novel class of cancer immunotherapeutics that are changing the face of cancer therapy.
Jennifer Altomonte, Teresa Krabbe
core   +1 more source

The combination therapy of oncolytic virotherapy

open access: yesFrontiers in Pharmacology
Introduction: Compared to other cancer immunotherapies, oncolytic viruses possess several advantages, including high killing efficiency, excellent targeting capabilities, minimal adverse reactions, and multiple pathways for tumor destruction.
Yue Wang   +6 more
doaj   +1 more source

Syncytia Formation in Oncolytic Virotherapy

open access: yesMolecular Therapy: Oncolytics, 2019
Oncolytic virotherapy uses replication-competent virus as a means of treating cancer. Whereas this field has shown great promise as a viable treatment method, the limited spread of these viruses throughout the tumor microenvironment remains a major ...
Chase Burton, Eric Bartee
doaj   +1 more source

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada   +13 more
wiley   +1 more source

Engineered oncolytic virus coated with anti-PD-1 and alendronate for ameliorating intratumoral T cell hypofunction

open access: yesExperimental Hematology & Oncology
Background Glioblastoma is a highly aggressive and devastating primary brain tumor that is resistant to conventional therapies. Oncolytic viruses represent a promising therapeutic approach for glioblastoma by selectively lysing tumor cells and eliciting ...
Yufu Zhu   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy